3BP pursues several in-house development programs to identify novel targeted radiotherapeutics and in vivo imaging agents. All current projects focus on oncology indications with a high medical need and poor patient prognosis. As therapeutics and imaging diagnostics can be developed based on the same radiolabeled peptide, the resulting “theranostic” combination can be used to personalize cancer treatment, thereby improving patient outcome. Specific properties of peptides, such as rapid elimination from the circulation and superior tumor penetration, make them ideal candidates for applications in nuclear medicine. As experimental therapies can be evaluated in micro-dosing studies, a clinical proof of concept can be achieved rapidly and cost-effectively.
3BP is aiming at early partnering of the oncology projects, which are addressing G protein coupled receptors, cell adhesion molecules, and extracellular matrix proteins.